A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)
Case Comprehensive Cancer Center
Case Comprehensive Cancer Center
City of Hope Medical Center
City of Hope Medical Center
Mayo Clinic
Fred Hutchinson Cancer Center
Mayo Clinic
Roswell Park Cancer Institute
University of Chicago
Barbara Ann Karmanos Cancer Institute
University of Texas Southwestern Medical Center
Wake Forest University Health Sciences
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
University of Washington
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Mayo Clinic
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)
National Cancer Institute (NCI)
City of Hope Medical Center
National Cancer Institute (NCI)
Northside Hospital, Inc.
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Northside Hospital, Inc.
European Organisation for Research and Treatment of Cancer - EORTC
Northside Hospital, Inc.
Case Comprehensive Cancer Center
Hoag Memorial Hospital Presbyterian
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)